Results 171 to 180 of about 77,990 (218)

Chimeric Antigen Receptor T-Cell Therapy: More Than an Anti-Cancer Drug. [PDF]

HLA
Schenk HCM, Gille I, Arana C, Rovira J, Palou E, Diekmann F, Roelen DL, Heemskerk MHM, Heidt S.   +8 more
europepmc   +1 more source

Bridging practices prior to brexucabtagene autoleucel for mantle cell lymphoma in the United Kingdom: An analysis of modality, response, toxicity and survival

British Journal of Haematology, EarlyView.
Summary Bridging therapy (BT) prior to brexucabtagene autoleucel (brexu‐cel) in mantle cell lymphoma (MCL) is supported by limited evidence. Here, we report BT modality and outcome in 176 patients at 15 centres in the United Kingdom. BT was delivered to 90% (158/176), the majority receiving standard chemotherapy +/− radiotherapy (53%) (SD chemo +/− RT)
Maeve A. O'Reilly, William Wilson, Bernard Maybury, Andrea Kuhnl, Claire Roddie, Ben Uttenthal, Rod Johnson, Rajesh Alajangi, Thomas Creasey, Ahmed Abdulgawad, Carlos Gonzalez Arias, Sunil Iyengar, Graeme Ferguson, Katerina Panopoulou, Alison Delaney, Angharad Pryce, Lourdes Rubio, Ceri Jones, Jonathan Lambert, Shweta Gupta, Amrith Mathew, Shenbagaram Kasivisvanathan, Olateni Awofisayo, Shreyas Hanmantgad, Graham P. Collins, Caroline Besley, Frances Seymour, Robin Sanderson, Sridhar Chaganti   +28 more
wiley   +1 more source

Circulating tumour cells (CTCs) in haematological malignancies: Advances in biology and clinical relevance with a focus on multiple myeloma

British Journal of Haematology, EarlyView.
Spatial heterogeneity limits the sensitivity of bone marrow biopsies, resulting in false‐negative findings. Circulating tumour cells (CTCs) provide a systemic, stratified monitoring approach, using flow cytometry for high tumour burden and EuroFlow or allele‐specific oligonucleotide PCR (ASO‐PCR) for minimal residual disease to enable early relapse ...
Chin‐Mu Hsu, Jui‐Feng Hsu, Jee‐Fu Huang, Yi‐Chang Liu   +3 more
wiley   +1 more source

Common gamma chain cytokines-driven optimization of chimeric antigen receptor T cells: Mechanistic insights and future directions. [PDF]

World J Clin Oncol
Zuo DB, Chen ZH, Jin YM, Sang M, Sun XD, Guo A, Li XY, Wu JX, Ji KK, Zhou H.   +9 more
europepmc   +1 more source

Special Issue "Targeting CAR T-Cell Therapy: Molecular Research and Its Future Implication". [PDF]

Int J Mol Sci
Bouziana S.
europepmc   +1 more source

Efficacy of immune checkpoint inhibitors in paediatric, adolescent and young adults with primary refractory or relapsed classical Hodgkin lymphoma: A national multicentre real‐world study

British Journal of Haematology, EarlyView.
Summary Classical Hodgkin lymphoma (cHL) is the most frequent lymphoma in children, adolescents and young adults (CAYA). Despite therapeutic advances, around 15% of patients relapse or have refractory (R/R) disease. Conventional salvage regimens remain effective but are associated with substantial long‐term toxicity. Immune checkpoint inhibitors (CPIs),
Marlène Pouthier, Nathalie Garnier, Amaury Leruste, Charlotte Rigaud, Catherine Curtillet, Stéphane Ducassou, Marilyne Poirée, Marie‐Emilie Dourthe, Cécile Pochon, Marie‐Laure Couec, Jacinthe Bonneau‐Lagacherie, Françoise Montravers, Sabah Boudjemaa, Bénédicte Jonca, Stéphanie Haouy, Thierry Leblanc, Judith Landman Parker, Mathieu Simonin   +17 more
wiley   +1 more source

CD2 costimulation breaks the CD28 vs. 4-1BB tradeoff in CAR T cells. [PDF]

Mol Ther Oncol
Posey AD.
europepmc   +1 more source

Immunoprofiling, sex‐ and age‐related determinants of treatment response in paediatric, adolescent and young adult Hodgkin lymphoma

British Journal of Haematology, EarlyView.
Multimodal integration of sex‐ and age‐related immune‐gene signatures with baseline tumor burden (TMTV1) improves prediction of treatment response in adolescents and young adults with classical Hodgkin lymphoma. Summary The study investigates how sex and age influence treatment response in paediatric, adolescent and young adult (AYA) classical Hodgkin ...
Valli De Re, Egesta Lopci, Giulia Brisotto, Caterina Elia, Angelo Vitullo, Veronica Paduano, Mariangela De Zorzi, Lara Mussolin, Paola Quarello, Simona Bianchi, Salvatore Buffardi, Alberto Garaventa, Paola Muggeo, Marta Pillon, Alessandra Sala, Luciana Vinti, Emanuele d'Amore, Christine Mauz‐Korholz, Maurizio Mascarin, on behalf of the AIEOP Hodgkin's Lymphoma Study Group, Alberto Garaventa, Alessandra Sala, Antonella Sau, Assunta Tornesello, Daniela Galimberti, Domenico Sperlì, Elena Facchini, Eulalia Galea, Federico Verzegnassi, Fiorina Giona, Francesca Rossi, Fulvio Porta, Irene D’Alba, Katia Perruccio, Luciana Vinti, Marco Zecca, Marta Pillon, Massimo Provenzi, Maurizio Bianchi, Maurizio Mascarin, Monica Cellini, Nadia Vacca, Paola Muggeo, Patrizia Bertolini, Piero Farruggia, Raffaella De Santis, Roberta Pericoli, Rosamaria Mura, Salvatore Buffardi, Salvatore D’Amico, Sayla Bernasconi, Simona Rinieri, Simone Cesaro, Tommaso Casini, Valerio Cecinati   +54 more
wiley   +1 more source

Genetic engineering and allogeneic optimization of Vδ1 γδ CAR-T cells (ADI-270) for cancer immunotherapy. [PDF]

J Immunother Cancer
Liu W, Moriarity BS, Webber BR.
europepmc   +1 more source

Serum free light chain concentration and ratio‐based criterion for myeloma‐defining event, in its current version, is untenable

British Journal of Haematology, EarlyView.
Summary Clinical decision‐making based on myeloma‐defining event criteria using thresholds for involved serum free light chain level of 10 mg/dL and ratio of involved to uninvolved light chain of >100 is a poor indicator for the risk of progression to multiple myeloma.
Gurmukh Singh
wiley   +1 more source